Vimarsana
Biggest News Aggregation in the World

Cure Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cure Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cure Ventures Today - Breaking & Trending Today

Eli Lilly warns of temporary supply of two insulin products | Nation & World News - Vimarsana News

Eli Lilly warns of temporary supply of two insulin products | Nation & World News

More than 8 million people in the US rely on insulin to survive, according to the American Diabetes Association

Source: komu.com
Eli Lilly warns of temporary short supply of two insulin products - Vimarsana News

Eli Lilly warns of temporary short supply of two insulin products

(CNN) — Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay

Source: kdrv.com
Kenai Therapeutics Raises $82M in Series A Financing - Vimarsana News

Kenai Therapeutics Raises $82M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Cure Ventures backs a cell therapy startup targeting Parkinson's - Vimarsana News

Cure Ventures backs a cell therapy startup targeting Parkinson's

BioPharma

Kenai Therapeutics Announces 82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases - Vimarsana News

Kenai Therapeutics Announces 82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

Kenai Therapeutics a biotechnology company leveraging induced pluripotent stem cell iPSC technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders today announced an 82 million Series A financing coled by Alaska Permanent Fund Corporation Cure Ventures and The Column Group with participation from Euclidean Capital and Saisei Ventures.